Mcquire
Leslie W. Mcquire, Cambrige, MA US
Patent application number | Description | Published |
---|---|---|
20090306373 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS - This invention relates generally to compounds and pharmaceutical compositions for the treatment of myosin heavy chain (MyHC)-mediated conditions, and in particular, cardiovascular conditions. | 12-10-2009 |
20110105496 | Methods For The Treatment Of Myosin Heavy Chain-Mediated Conditions Using 4,7-Dihydrothieno[2,3-B]Pyridine Compounds - This invention relates generally to methods for the treatment of myosin heavy chain (MyHC)-mediated conditions, and in particular, cardiovascular conditions. | 05-05-2011 |
Leslie Wighton Mcquire, Warren, NJ US
Patent application number | Description | Published |
---|---|---|
20100261698 | ORGANIC COMPOUNDS - The present invention provides novel organic compounds of Formula I: | 10-14-2010 |
20110082129 | ORGANIC COMPOUNDS - The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof. | 04-07-2011 |
20120258954 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors - The present invention provides a compound of formula (I): | 10-11-2012 |
20130096105 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors - The present invention provides a compound of formula (I): | 04-18-2013 |
20140288126 | ORGANIC COMPOUNDS - The present invention provides novel organic compounds of Formula (I): methods of use, and pharmaceutical compositions thereof. | 09-25-2014 |
20150045398 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors - The present invention provides a compound of formula (I): | 02-12-2015 |
Leslie Wighton Mcquire, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20110014186 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS - The present invention provides a compound of formula (I): | 01-20-2011 |
20110112076 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS - The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I). | 05-12-2011 |
20140031399 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS - The present invention provides a compound of formula (I): | 01-30-2014 |